Search results
Results from the WOW.Com Content Network
Elmarit-S 1:2.8/30 mm ASPH. CS; Elmarit-S 1:2.8/45 mm ASPH. Elmarit-S 1:2.8/45 mm ASPH. CS; For the Leica L Mount. Elmarit-TL 18 mm f/2.8 ASPH. APO-Macro-Elmarit-TL 60 f/2.8 ASPH. Vario-Elmarit-SL 24-70 f/2.8 ASPH. Vario-Elmarit-SL 1:2.8–4 / 24–90 ASPH. APO-Vario-Elmarit-SL 1:2.8–4 / 90–280; For the Four Thirds mount [a 1] D Vario ...
Current Elmar lenses have a maximum aperture of f/3.8 or f/4, as in the Elmar-M 24 mm f/3.8 and Tri-Elmar-M 16-18-21 mm f/4. [1] The term Elmar is sometimes combined with: Super, Tele, APO, Macro or Vario. Leica also uses the name Elmarit for some lenses.
The Leica Vario-Elmarit-SL 24-90mm F2.8-4 ASPH is an interchangeable standard zoom lens for Leica L mount, announced by Leica on October 20, 2015. [1]A review in PCMag UK praised the lens for its sharpness, low distortion and weatherproof, optically stabilised design, while also drawing attention to its vignetting of up to 5.5 stops at 24mm.
There are some variations in lens markings, depending on which camera it was bundled with initially; engraved on the ring around the front element for the version bundled with the Panasonic DMC-L1, the brand ("LEICA") is by itself on one side, opposite the lens name and data ("D VARIO-ELMARIT 1:2.8–3.5/14-50 ASPH.
The Prescribing Information follows one of two formats: "physician labeling rule" format or "old" (non-PLR) format. For "old" format labeling a "product title" may be listed first and may include the proprietary name (if any), the nonproprietary name, dosage form(s), and other information about the product. The other sections are as follows:
The EF 28mm lenses are a group of prime lenses made by Canon that share the same focal length. These lenses use the EF type mount that fits the Canon EOS line of cameras. When used on a camera body with an APS-C sensor, such as the Canon EOS 700D , it provides a narrower field of view, equivalent to a 45 mm lens mounted on a 35 mm frame body.
Summary: Side effects of bremelanotide with a ≥1% incidence in a combined analysis of two phase 3, double-blind, placebo controlled-clinical trials evaluating safety and efficacy at a daily dosage of 1.75 mg. Nausea was very common and occurred after a median time of 30 minutes for a median duration of 2.4 hours.
Day 1: INH at 1/3 or 1/4 dose; Day 2: INH at 1/2 dose; Day 3: INH at full dose; Day 4: RMP at 1/3 or 1/4 dose; Day 5: RMP at 1/2 dose; Day 6: RMP at full dose; Day 7: EMB at 1/3 or 1/4 dose; Day 8: EMB at 1/2 dose; Day 9: EMB at full dose; No more than one test dose per day should be given, and all other drugs should be stopped while test ...